Literature DB >> 15839305

Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer.

Wei Hu1, John J Kavanagh, Michael Deaver, Dennis A Johnston, Ralph S Freedman, Claire F Verschraegen, Subrata Sen.   

Abstract

The STK15 (also known as Aurora-A/BTAK) gene localized on chromosome 20q13 and encoding a centrosome-associated serine/threonine kinase is amplified and overexpressed in multiple human tumor cell types. Overexpression of this gene is involved in tumorigenic transformation, induction of centrosome duplication-distribution abnormalities, and aneuploidy in mammalian cells. To examine the potential role of STK15 in ovarian tumorigenesis, its mRNA and protein expression status were examined in cells grown in culture from 15 ovarian cancer specimens using semiquantitative RT-PCR and Western blot analysis. Normal ovarian surface tissues and the near diploid nontumorigenic breast epithelial cell line MCF10 were used as controls. The status of STK15 correlated with transformation-associated cellular phenotypes including tumorigenicity in nude mice, p53 expression level, and chromosomal ploidy. For chromosome ploidy analyses, FISH was carried out with direct fluorescence-labeled a-satellite probes for chromosome 3 and 17. STK15 mRNA was found overexpressed in 10 of the 15 ovarian cancer cell cultures. Five of these cell cultures revealed a truncated form of the STK15 protein with a molecular mass of 36 kDa. When tested for tumorigenicity in nude mice, 9 of the 10 cell cultures that overexpressed STK15 mRNA formed tumors in nude mice, while only one of the five cell cultures with no overexpression did. Cells overexpressing STK15 mRNA showed significant correlation with chromosome 3 polysomy. Six of the 13 (46%) cell cultures analyzed for p53 expression revealed overexpression of p53 and five of these six (83%) also overexpressed STK15. Four of the remaining seven cultures (57%) with overexpression of STK15 revealed minimal or no expression of p53. These results demonstrate that overexpression of STK15 significantly correlates with nude mice tumorigenicity and chromosomal aneuploidy in human ovarian cancer cells grown in vitro. Additionally, cells overexpressing STK15 also revealed frequent coordinate loss of wild-type p53 function manifested either as highly expressed intense staining reflective of a mutant form of p53 or almost complete absence of p53 staining. Overexpression of STK15 with coordinate loss of wild-type p53 function thus appears to play an important role in ovarian tumorigenesis and offers a novel molecular target in designing effective therapy of human ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15839305     DOI: 10.3727/096504005775082101

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  23 in total

Review 1.  New aspects of neuroblastoma treatment: ASPHO 2011 symposium review.

Authors:  Peter E Zage; Chrystal U Louis; Susan L Cohn
Journal:  Pediatr Blood Cancer       Date:  2012-02-29       Impact factor: 3.167

2.  Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2.

Authors:  Gong Yang; Bin Chang; Fan Yang; Xiaoqing Guo; Kathy Qi Cai; Xue Sherry Xiao; Huamin Wang; Subrata Sen; Mien-Chie Hung; Gordon B Mills; Sandy Chang; Asha S Multani; Imelda Mercado-Uribe; Jinsong Liu
Journal:  Clin Cancer Res       Date:  2010-04-27       Impact factor: 12.531

3.  SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity.

Authors:  Hyun-Seok Kim; Athanassios Vassilopoulos; Rui-Hong Wang; Tyler Lahusen; Zhen Xiao; Xiaoling Xu; Cuiling Li; Timothy D Veenstra; Bing Li; Hongtao Yu; Junfang Ji; Xin Wei Wang; Seong-Hoon Park; Yong I Cha; David Gius; Chu-Xia Deng
Journal:  Cancer Cell       Date:  2011-10-18       Impact factor: 31.743

4.  AURKA and BRCA2 expression highly correlate with prognosis of endometrioid ovarian carcinoma.

Authors:  Fan Yang; Xiaoqing Guo; Gong Yang; Daniel G Rosen; Jinsong Liu
Journal:  Mod Pathol       Date:  2011-03-25       Impact factor: 7.842

5.  Upregulation of FOXM1 induces genomic instability in human epidermal keratinocytes.

Authors:  Muy-Teck Teh; Emilios Gemenetzidis; Tracy Chaplin; Bryan D Young; Michael P Philpott
Journal:  Mol Cancer       Date:  2010-02-26       Impact factor: 27.401

6.  Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion.

Authors:  T-V Do; F Xiao; L E Bickel; A J Klein-Szanto; H B Pathak; X Hua; C Howe; S W O'Brien; M Maglaty; J A Ecsedy; S Litwin; E A Golemis; R J Schilder; A K Godwin; D C Connolly
Journal:  Oncogene       Date:  2013-01-21       Impact factor: 9.867

Review 7.  Basal-like subtype and BRCA1 dysfunction in breast cancers.

Authors:  Yasuo Miyoshi; Keiko Murase; Koushi Oh
Journal:  Int J Clin Oncol       Date:  2008-10-23       Impact factor: 3.402

8.  Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma.

Authors:  Xiaoying Shang; Susan M Burlingame; M Fatih Okcu; Ningling Ge; Heidi V Russell; Rachel A Egler; Rodney D David; Sanjeev A Vasudevan; Jianhua Yang; Jed G Nuchtern
Journal:  Mol Cancer Ther       Date:  2009-08-11       Impact factor: 6.261

Review 9.  Aurora A kinase (AURKA) in normal and pathological cell division.

Authors:  Anna S Nikonova; Igor Astsaturov; Ilya G Serebriiskii; Roland L Dunbrack; Erica A Golemis
Journal:  Cell Mol Life Sci       Date:  2012-08-03       Impact factor: 9.261

10.  Low nuclear grade but not cell proliferation predictive of pathological complete response to docetaxel in human breast cancers.

Authors:  Yasuo Miyoshi; Masafumi Kurosumi; Junichi Kurebayashi; Nariaki Matsuura; Masato Takahashi; Eriko Tokunaga; Chiyomi Egawa; Norikazu Masuda; Seung Jin Kim; Masatsugu Okishiro; Tetsu Yanagisawa; Satsuki Ueda; Tetsuya Taguchi; Yasuhiro Tamaki; Shinzaburo Noguchi
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-16       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.